Neutrophils News and Research

RSS

Researchers discover molecular sensor that detects wound-induced hydrogen peroxide

Hydrogen peroxide isn't just that bottled colorless liquid in the back of the medicine cabinet that's used occasionally for cleaning scraped knees and cut fingers. It's also a natural chemical in the body that rallies at wound sites, jump-starting immune cells into a series of events. A burst of hydrogen peroxide causes neutrophils, the immune system's first responders, to rush to the wound to fight microorganisms, remove damaged tissue and then start the inflammation process.

22 Nov 2011

Rothman researchers to develop gold standard definition for periprosthetic joint infection

A rise in periprosthetic joint infection (PJI) rates has the orthopedic community moving to develop it's first-ever agreed upon definition and diagnostic criteria to help better treat patients.

5 Nov 2011

Positive initial results from CytRx's INNO-206 Phase 1b/2 clinical trial for advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced favorable response and safety indications from a group of patients with advanced solid tumors (principally soft tissue sarcomas) in the Company's ongoing Phase 1b/2 clinical trial with INNO-206, its tumor-targeting conjugate of the commonly used chemotherapeutic agent doxorubicin.

31 Oct 2011

Patients with ANCA-associated vasculitis harbor Flt1 protein that blocks blood vessel repair

In some kidney diseases, patients have high blood levels of a protein that blocks blood vessel repair, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

28 Oct 2011

New treatment approach for septic Listeria infection

Research underway at the Trudeau Institute could lead to new treatments for people sickened by Listeria and other sepsis-causing bacteria. Dr. Stephen Smiley's laboratory has published a study in the scientific journal Infection and Immunity that supports a new approach to treating these infections.

18 Oct 2011

ChemoCentryx commences CCX168 Phase II trial in ANCA-associated vasculitis

ChemoCentryx, Inc., today announced the initiation of a Phase II clinical trial for CCX168, an orally-administered small molecule for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), a disease which can lead to renal and pulmonary failure.

18 Oct 2011

Neutrophils inhibit restenosis in patients with atherosclerosis after stent implantation

A research team led by LMU's Professor Christian Weber has now shown that a specific cell type called neutrophils, and molecules that they secrete, inhibit this life-threatening complication - which is observed in up to one-third of all stent implantations.

7 Oct 2011

Calgary researchers discover new class of anti-inflammatory agents

By using a mouse model of inflammation researchers at the University of Calgary have discovered a new class of molecules that can inhibit the recruitment of some white blood cells to sites of inflammation in the body.

20 Sep 2011

ODAC recommends ApoPharma's Ferriprox for FDA approval to treat transfusional iron overload

ApoPharma Inc. today announced that the Oncologic Drugs Advisory Committee (ODAC) to the U.S. Food and Drug Administration (FDA) voted 10 - 2 to recommend that the FDA grant accelerated approval of Ferriprox (deferiprone), an oral iron chelator, for the treatment of patients with transfusional iron overload when current chelation therapy is inadequate.

15 Sep 2011

Plerixafor drug shows promise against WHIM syndrome

A new study reports that a drug already approved by the Food and Drug Administration for use in patients undergoing a bone marrow transplant may also have promise for treating people who have a rare immune deficiency known as WHIM syndrome.

3 Sep 2011

Sand fly's salivary components play a critical role in process for Leishmania

For millions of people who live under the constant threat of Leishmania infection, a new discovery by Brazilian scientists may lead to new breakthroughs, preventing these parasites from taking hold in the body or reducing the severity of infections once they occur.

2 Sep 2011

Neutrophils linked to growth and spread of cancer

Scripps Research Professor James Quigley, Staff Scientist Elena Deryugina, and colleagues had previously demonstrated that white blood cells known as neutrophils—bone marrow-derived cells that function as "first responders" at sites of acute inflammation—promote the growth of new blood vessels in normal, healthy tissue.

2 Sep 2011

Biomarkers may transform diagnosis of kidney disease

Acute kidney injury (AKI) is a common - but preventable -- complication after surgery that can lead to other complications or even death. The use and development of biomarkers will help physicians diagnose and treat acute kidney injury.

12 Aug 2011

Treatment with estrogen dramatically lowers rates of stomach cancer in male mice

Several types of cancer, including stomach, liver and colon, are far more common in men than in women. Some scientists have theorized that differences in lifestyle, such as diet and smoking, may account for the discrepancy, but growing evidence suggests that the differences are rooted in basic biological differences between men and women.

14 Jul 2011

GWAS identifies 15 gene variants responsible for diversity of white blood cell counts

A trio of large-scale genome-wide association studies, or GWAS, have identified more than 15 gene variants responsible for the diversity of white blood cell counts among whites, African-Americans, and Japanese.

1 Jul 2011

Rogue super-activated neutrophils may cause organ damage in parts unconnected to injury

A study from scientists at Queen Mary, University of London, sheds new light on why people who experience serious trauma or go through major surgery, can suffer organ damage in parts of the body which are seemingly unconnected to the injury.

27 Jun 2011

Researchers identify nine blood proteins that alter with age

Loss of muscle mass is not only associated with disease, such as HIV and cancer, but also with the normal aging process. Anabolic steroids are sometimes used to reverse loss of lean muscle tissue but they can have unwanted side effects.

20 Jun 2011

$Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS$

Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS

Telik, Inc. today announced the initiation of a Phase 2 clinical trial to evaluate oral Telintra in patients with Revlimid refractory or resistant, deletion 5q myelodysplastic syndrome.

8 Jun 2011

Intrexon, Halozyme partner to develop subcutaneous alpha 1-antitrypsin for A1AT deficiency

Halozyme Therapeutics, Inc. and Intrexon Corporation, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 in the development of a subcutaneous injectable formulation of Intrexon Corporation's recombinant human alpha 1-antitrypsin (rHuA1AT).

7 Jun 2011

Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO

Celator Pharmaceuticals today announced positive clinical results in elderly patients with newly-diagnosed secondary acute myeloid leukemia (sAML) treated with CPX-351 Liposome Injection.